1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited

SMSPHARMA.NS
SMS Pharmaceuticals LimitedIN flagNational Stock Exchange of India
405.85
INR
-1.20
- -
38.01BMarket Cap
SMS Pharmaceuticals Limited
SMSPHARMA.NS
(National Stock Exchange of India)

Recent

price

405.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
22.56
21.38
24.49
58.6
68.42
71.25
51.46
54.4
54.56
48.12
66.25
60.84
61.4
83.45
92.39
- -
98.59
Revenue per Share
0.84
0.11
2.53
2.31
4.16
4.83
3.37
3.75
4.73
3.73
7.39
7.35
-0.83
5.89
8.16
- -
11.34
Basic EPS, GAAP
-0.87
-0.32
-8.35
1.29
3.53
-3.26
5.94
2.75
1.76
-0.36
-7.24
2.1
-0.88
-0.24
-4.92
- -
- -
Free Cash Flow per Basic Share
0.23
0.17
- -
0.22
0.23
0.24
0.24
0.24
0.3
0.6
- -
0.3
0.3
0.3
0.4
- -
- -
Dividend per Share
3.54
3.65
5.65
7.83
10.89
14.64
16.58
18.91
22.15
24.08
30.26
36.13
34.98
39.38
45.91
- -
1.04
Book Value per Share
21.9
22.01
24.33
25.07
30.05
26.93
30.04
33.56
37.89
41.04
48.31
55.39
54.23
63.04
75.25
- -
87.04
Tangible Book Value per Share
100
100
100
88
85
85
85
85
85
85
85
85
85
85
85
- -
90
Basic Weighted Avg Shares
2,259
2,141
2,452
5,180
5,793
6,032
4,356
4,605
4,618
4,073
5,608
5,150
5,197
7,065
7,827
8,869
8,869
Sales/Revenue/Turnover
11.67
14.47
-19.99
8.55
11.93
11.67
12.85
15.96
15.35
14.24
17.63
16.01
4.33
12.07
13.37
14.81
14.81
Operating Margin (%)
126
126
137
129
172
194
192
199
193
221
223
322
321
315
343
399
399
Depreciation Expense
84
11
253
204
352
409
285
317
400
316
625
622
-71
498
691
1,020
1,020
Net Income, GAAP
19.95
19.75
14.63
36.33
47.77
26
14.35
32.97
33.52
35.6
33.09
0.9
27.39
25.57
27.01
24.55
24.55
Effective Tax Rate (%)
3.71
0.53
10.33
3.93
6.08
6.78
6.54
6.89
8.67
7.75
11.15
12.08
-1.36
7.05
8.83
11.5
11.5
Profit Margin (%)
500
381
696
244
372
62
104
470
650
736
1,139
1,806
1,557
2,022
2,301
2,850
2,850
Working Capital
901
818
536
694
823
893
742
714
622
730
1,506
1,516
1,217
1,221
1,394
1,716
1,716
LT Debt
2,199
2,211
2,441
2,218
2,548
2,284
2,547
2,845
3,219
3,482
4,105
4,703
4,605
5,363
6,396
7,858
7,858
Total Equity
5.53
6.32
-10.79
7.55
9.27
12.97
12
11.81
10.52
7.7
11.3
11.69
2.25
8.29
8.64
9.43
9.43
Return on Invested Capital (%)
12.11
0.54
12.63
13.89
18.88
19.55
14.29
13.98
14.95
11.21
15.92
14.86
1.46
11.45
12.58
22.23
22.23
Return on Capital (%)
36.95
3.16
54.41
32.43
43.69
37.84
21.56
21.14
23.04
16.14
27.19
22.14
-2.35
15.83
19.14
51.21
51.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
2,030
- -
1,934
LT Borrowings
1,213
- -
1,716
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
- -
94
Market Capitalization
21,331
27,401
33,721

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
6,611
- -
6,380
Cash, Cash Equivalents & STI
1,021
- -
495
Accounts Receivable, Net
2,214
- -
2,159
Inventories
3,175
- -
3,512
Total Current Liabilities
3,752
- -
3,530
Payables & Accruals
- -
- -
- -
ST Debt
2,030
- -
1,934
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.35%
14.21%
22.85%
Free Cash Flow
311.09%
334.96%
71.19%
Net Income, GAAP
-74.73%
-166.28%
47.52%
Sales/Revenue/Turnover
5.69%
10.55%
13.3%
Total Cash Common Dividend
- -
- -
4.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,353
1,666
1,615
2,430
7,065
2025
1,645
1,967
1,734
2,482
7,827
2026
1,960
2,424
2,104
2,379
8,869

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.1
1.39
1.36
- -
5.89
2025
1.95
1.67
2.15
2.4
8.16
2026
2.31
2.84
2.59
3.58
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
0.4
2026
- -
- -
- -
- -
- -
Similar Companies
AstraZeneca PLC (AZNCF)
Marksans Pharma Limited (MARKSANS.BO)
JCR Pharmaceuticals Co., Ltd. (JCRRF)
Gland Pharma Limited (GLAND.BO)
Amgen Inc. (AMG.DE)
Daiichi Sankyo Company, Limited (DSKYF)
Business
SMS Pharmaceuticals Limited is an integrated pharmaceutical company specializing in the manufacture and export of Active Pharmaceutical Ingredients (APIs) and complex intermediates across multiple therapeutic categories including anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, and anti-retroviral segments. The company offers over 45 products to more than 800 customers in over 75 countries, with a global leadership position in 10+ therapeutic products. Key product offerings include APIs such as Ibuprofen, Tenofavir, Famotidine, Tadalafil, Levetiracetam, Lamotrigine, Sitagliptin, Rizatriptan Benzoate, Sumatriptan Succinate, and others, supported by USFDA, EUGMP, KFDA, CDSCO, and PMDA certifications. Founded in 1995 and headquartered in Hyderabad, India, SMS Pharmaceuticals operates several manufacturing facilities with a focus on quality through extensive quality management and regulatory compliance. In the last 1-2 years, SMS Pharmaceuticals has undertaken significant capacity expansion and vertical integration initiatives, including a ₹250 crore investment program aimed at scaling manufacturing, strengthening environmental systems, and enhancing new product introductions and contract manufacturing organization (CMO) business. The company continues to broaden its product portfolio, targeting the addition of 8-10 new products in existing and emerging therapeutic areas within the next 12-18 months. Recent strategic developments include successful inspections by regulatory authorities such as the USFDA, the expansion of a dedicated peptide-focused R&D center, and a greenfield CDMO site in Andhra Pradesh. It has also strengthened its market presence through a joint venture with Chemo and an investment in VKT Pharma to increase product offerings and deepen its footprint in Europe. SMS Pharmaceuticals focuses on leveraging a diversified product portfolio with a dual emphasis on high-margin and high-volume API products like Ibuprofen, where it aims for global scale leadership. The company prioritizes backward integration to improve profitability and cost efficiency while doubling its R&D expenditure over the coming period to support a robust pipeline of high-potential molecules, facilitated by multiple DMF, CEP, and dossier filings. The company maintains a strong export focus with extensive operations across international markets including the U.S., Europe, and Asia. This comprehensive operational and strategic approach positions SMS Pharmaceuticals as a leading API manufacturer with a solid foundation in regulatory compliance, global market reach, and ongoing capacity and product innovations, driven by sustained investment in research and infrastructure. Its continued focus on growth through capacity expansion, new product development, and strategic partnerships defines its current business trajectory.